TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Key Takeaways Teva's three innovative branded drugs, Austedo, Ajovy and Uzedy, are recording strong sales growth Generics sales face U.S. competition and impact from the Japan divestment.Teva guides 2025 generics growth to be flat to up in low single digits in constant currency.Teva Pharmaceutical Industries Limited’s (TEVA) shares have risen 19.4% in the past month.  A key driver of the stock price increase was its mixed second-quarter results announced on July 30. Teva’s second-quarter results were mixed ...